If Trikafta Isn’t Good Enough for ICER, What Drug Is?
TIMMERMAN REPORT - MAY 2020 Jessica Sagers, PhD
The Institute for Clinical and Economic Review (ICER) recently concluded that Trikafta, a new, groundbreaking cystic fibrosis drug developed by Vertex, isn't worth its price. But ICER's cost-effectiveness analyses routinely refuse to include variables that do not suit the organization's political agenda. Insisting on modeling a drug's launch price as its price forever without taking into account the fact that it will go generic is distinctly disingenuous.
Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience when you browse our website, and also allows us to improve our site. By continuing, you accept the use of these cookies.
Before accessing these resources, the reader must review and acknowledge the following terms and conditions
By clicking “I Agree”, you acknowledge the following terms and conditions.
Publications are provided for informational purposes only and do not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, nor do they constitute an offer or endorsement of RA Capital's investment advisory or other services by RA Capital Management (“RA Capital”). The content of the publications neither constitutes investment advice nor offers any opinion with respect to the suitability of any security. Accounts managed by RA Capital may invest in certain companies referenced in the publications; however, RA Capital makes no guarantees as to accuracy or completeness of views expressed in the publications. Views expressed in the publications are subject to change, and may have become unreliable for various reasons, including changes in market conditions or economic circumstances. Any disclosures as to RA Capital Management is subject to change and is only valid as of the date the statement was made. Any references, either general or specific, to securities and/or issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, advice or recommendations to purchase, continue to hold, or sell such securities. Certain current and prior investments may be highlighted in order to provide additional information regarding RA Capital’s investment strategy, the types of investments it pursues, and anticipated exit strategies. By accessing the publications, the reader agrees that he/she will not copy, reproduce, republish, upload, post, transmit, alter, or distribute the publications in any way that is inconsistent with the purposes for which they are offered, without the prior written consent of RA Capital.
This disclaimer is in addition to all disclaimers found on the RA Capital website.
